Shopping Cart 0
Cart Subtotal
USD 0

TRACON Pharmaceuticals Inc (TCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. Its TRC102, is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In addition, it also offers products for the treatment of fibrosis, prostate cancer, and hematologic malignancies such as myeloma. TRACON conducts pre-clinical studies for various products. The company works in collaboration with universities and institutions. TRACON is headquartered in San Diego, California, the US.

TRACON Pharmaceuticals Inc (TCON)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

TRACON Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

TRACON Pharma Raises USD27 Million in Series B Venture Financing 13

Private Equity 15

Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 15

Partnerships 16

Tracon Pharma Enters into Research Agreement with Tufts Medical Center 16

Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 17

Licensing Agreements 19

Ambrx Enters into Licensing Agreement with TRACON Pharma 19

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 20

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 22

Equity Offering 23

TRACON Pharma to Raise up to USD11.5 Million in Public Offering of Shares 23

TRACON Pharma to Raise USD68 Million in Public Offering of Shares 24

Tracon Pharma Raises USD38.7 Million in Private Placement of Shares and Warrants 25

Tracon Pharma to Raise USD14.33 Million in Public Offering of Shares 27

TRACON Pharma Files Registration Statement for Public Offering of Shares 28

TRACON Pharma Raises USD1 Million in Private Placement of Shares 29

TRACON Pharma Raises USD17.4 Million in Public Offering of Shares 30

TRACON Pharma Raises USD36 Million in IPO 32

TRACON Pharma Raises USD5 Million in Private Placement of Shares 34

TRACON Pharmaceuticals Inc-Key Competitors 36

TRACON Pharmaceuticals Inc-Key Employees 37

TRACON Pharmaceuticals Inc-Locations And Subsidiaries 38

Head Office 38

Recent Developments 39

Financial Announcements 39

Aug 08, 2018: TRACON Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 39

May 09, 2018: TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 41

Feb 28, 2018: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update 42

Nov 07, 2017: TRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update 44

Aug 08, 2017: TRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update 46

May 10, 2017: TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update 48

Feb 28, 2017: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 50

Research And Development 51

Apr 10, 2017: TRACON receives Most Innovative Clinical Trial Design award for Phase III angiosarcoma trial 51

Corporate Communications 52

May 30, 2018: TRACON Pharmaceuticals Appoints Mark Wiggins As Chief Business Officer 52

Apr 09, 2018: TRACON Pharmaceuticals Appoints Ted Wang As Board Director 53

Dec 04, 2017: TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board 54

Product News 55

11/09/2017: TRACON Pharmaceuticals Presents Updated Data from Phase 1b/2 Study of TRC105 and Votrient in Patients with Soft Tissue Sarcoma Including Angiosarcoma 55

08/16/2017: TRACON Pharmaceuticals Announces Positive Results from National Cancer Institute Phase 1/2 Trial of TRC105 and Nexavar in Hepatocellular Cancer Published in Clinical Cancer Research 56

02/12/2018: Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients with Refractory Wet Age-Related Macular Degeneration 57

01/19/2018: TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients 58

Clinical Trials 59

Jun 13, 2018: TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combination With A PD-1 Antibody In Murine Models Of Colorectal Cancer 59

Nov 29, 2017: TRACON Doses First Patient in Phase 1b Study of TRC105 with Opdivo in Patients with Lung Cancer 60

Oct 15, 2017: TRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung Cancer 61

Sep 07, 2017: TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta in Renal Cell Carcinoma 62

Jul 25, 2017: Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration 63

Jun 05, 2017: TRACON Pharmaceuticals Presents Positive Clinical Data from TRC105 Study at American Society of Clinical Oncology 2017 Annual Meeting 64

May 25, 2017: TRACON To Present Clinical Data for Carotuximab at Upcoming ASCO Annual Meeting 65

May 11, 2017: TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia 66

Apr 10, 2017: TRACON Awarded 'Most Innovative Trial Design' for Phase 3 TAPPAS Clinical Trial of TRC105 in Angiosarcoma at 2017 Clinical and Research Excellence Awards 67

Feb 16, 2017: TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma 68

Feb 09, 2017: TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma 69

Jan 03, 2017: TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma 70

Appendix 71

Methodology 71

About GlobalData 71

Contact Us 71

Disclaimer 71


List Of Figure

List of Figures

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

TRACON Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TRACON Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

TRACON Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

TRACON Pharma Raises USD27 Million in Series B Venture Financing 13

Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 15

Tracon Pharma Enters into Research Agreement with Tufts Medical Center 16

Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 17

Ambrx Enters into Licensing Agreement with TRACON Pharma 19

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 20

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 22

TRACON Pharma to Raise up to USD11.5 Million in Public Offering of Shares 23

TRACON Pharma to Raise USD68 Million in Public Offering of Shares 24

Tracon Pharma Raises USD38.7 Million in Private Placement of Shares and Warrants 25

Tracon Pharma to Raise USD14.33 Million in Public Offering of Shares 27

TRACON Pharma Files Registration Statement for Public Offering of Shares 28

TRACON Pharma Raises USD1 Million in Private Placement of Shares 29

TRACON Pharma Raises USD17.4 Million in Public Offering of Shares 30

TRACON Pharma Raises USD36 Million in IPO 32

TRACON Pharma Raises USD5 Million in Private Placement of Shares 34

TRACON Pharmaceuticals Inc, Key Competitors 36

TRACON Pharmaceuticals Inc, Key Employees 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

TRACON Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.